An item in BioWorld Today, July 6, 2011, incorrectly said that Intrexon Corp., of Blacksburg, Va., is selling 6 million shares of New York-based Ziopharm Oncology Inc. While the shares are being registered as indicated by the SEC filing Friday, Intrexon has no intention of selling the shares. Intrexon acquired the shares in January as part of a channel partnership with Ziopharm for DNA-based cancer therapeutics.

Editor's note: The correction has been made in BioWorld Online.